Q1 Earnings Estimate for Sage Therapeutics Issued By Wedbush

Sage Therapeutics, Inc. (NASDAQ:SAGE) – Research analysts at Wedbush boosted their Q1 2025 earnings per share (EPS) estimates for Sage Therapeutics in a report issued on Wednesday, November 20th. Wedbush analyst L. Chico now anticipates that the biopharmaceutical company will post earnings per share of ($1.31) for the quarter, up from their previous estimate of ($1.38). Wedbush has a “Neutral” rating and a $8.00 price objective on the stock. The consensus estimate for Sage Therapeutics’ current full-year earnings is ($6.50) per share. Wedbush also issued estimates for Sage Therapeutics’ Q2 2025 earnings at ($1.16) EPS, Q3 2025 earnings at ($1.18) EPS, Q4 2025 earnings at ($1.18) EPS, FY2025 earnings at ($4.83) EPS, FY2026 earnings at ($3.31) EPS, FY2027 earnings at ($0.79) EPS and FY2028 earnings at ($0.29) EPS.

A number of other research analysts have also recently issued reports on SAGE. Royal Bank of Canada upgraded Sage Therapeutics from an “underperform” rating to a “sector perform” rating and set a $4.00 price objective for the company in a research note on Thursday. Bank of America lowered their price target on Sage Therapeutics from $11.00 to $6.00 and set an “underperform” rating for the company in a research report on Wednesday, October 9th. HC Wainwright reissued a “neutral” rating and set a $14.00 price objective on shares of Sage Therapeutics in a research report on Wednesday, November 20th. Raymond James reaffirmed a “market perform” rating on shares of Sage Therapeutics in a report on Thursday, October 10th. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Sage Therapeutics in a report on Wednesday, November 20th. Three research analysts have rated the stock with a sell rating, seventeen have issued a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus target price of $12.83.

Sage Therapeutics Stock Performance

SAGE stock opened at $5.17 on Monday. The firm has a 50 day moving average price of $6.70 and a 200-day moving average price of $9.02. Sage Therapeutics has a 52-week low of $4.62 and a 52-week high of $28.26. The firm has a market capitalization of $316.25 million, a price-to-earnings ratio of -0.93 and a beta of 0.92.

Sage Therapeutics (NASDAQ:SAGE) last posted its quarterly earnings data on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) EPS for the quarter, missing the consensus estimate of ($1.52) by ($0.01). The business had revenue of $11.87 million for the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative return on equity of 50.29% and a negative net margin of 317.29%. The company’s revenue was up 337.1% on a year-over-year basis. During the same period in the previous year, the firm earned ($2.81) EPS.

Institutional Trading of Sage Therapeutics

A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. grew its stake in shares of Sage Therapeutics by 8.1% during the 1st quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock valued at $107,781,000 after purchasing an additional 432,013 shares during the period. RTW Investments LP boosted its holdings in shares of Sage Therapeutics by 2.0% in the third quarter. RTW Investments LP now owns 5,591,700 shares of the biopharmaceutical company’s stock worth $40,372,000 after buying an additional 111,123 shares during the last quarter. State Street Corp grew its position in Sage Therapeutics by 18.2% during the third quarter. State Street Corp now owns 2,926,239 shares of the biopharmaceutical company’s stock valued at $21,127,000 after buying an additional 451,377 shares during the period. Geode Capital Management LLC increased its holdings in Sage Therapeutics by 0.3% during the third quarter. Geode Capital Management LLC now owns 1,242,854 shares of the biopharmaceutical company’s stock valued at $8,975,000 after buying an additional 3,757 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD increased its holdings in Sage Therapeutics by 69.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 811,934 shares of the biopharmaceutical company’s stock valued at $15,217,000 after buying an additional 333,805 shares during the last quarter. Hedge funds and other institutional investors own 99.22% of the company’s stock.

About Sage Therapeutics

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.